NCT04196465View on ClinicalTrials.gov

Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 9, 2019

Primary Completion Date

September 9, 2026

Study Completion Date

September 26, 2026

Conditions
Subjects With Resectable and Localized Gastric CancerSubjects With Resectable Esophageal Cancer or Liver CancerSubjects With Resectable Liver Cancer
Interventions
DRUG

IMC-001

IMC-001 is a fully human anti-programmed cell death ligand 1 (PD-L1) recombinant monoclonal antibody that strongly binds to PD-L1 to inhibit its binding to programmed cell death protein 1 (PD-1) or B7-1 (CD80). IMC-001 showed robust dose-dependent efficacy in animal models and no evidence of toxicity in cynomolgus monkeys

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER